Lecanemab: Appropriate Use Recommendations

Cummings, J., Apostolova, L., Rabinovici, G.D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R.C., Salloway, S.·2023·The Journal of Prevention of Alzheimer's Disease
DOI 10.14283/jpad.2023.30

Cited by (961)

Items 801–900 of 961

  1. Primary and secondary prevention strategies for reducing population-level dementia burden: A microsimulation modeling study
    Lynn van Rosmalen, Chiara C. Brück, Frank J. Wolters, Ron L. H. Handels, Inge M.C.M. de Kok · 2026 · Journal of Alzheimer s Disease
  2. A Keap1-Nrf2 protein-protein interaction inhibitor 4–95 ameliorates cognitive dysfunction by suppressing neuronal ferroptosis
    Ruyun Liu, Minzhen Wei, Lijuan Xu, Zhuo Qu, Jian-qiang Yu, Yue Liu, Wan-nian Zhang, Danfeng Zhang, Chunlin Zhuang · 2026 · Bioorganic Chemistry
  3. Initial specialist validation of clinical decision support recommendations from a machine learning-enabled digital cognitive assessment
    Ali Jannati, Claudio Toro‐Serey, Marissa Ciesla, Emma Chen, David Bates, John Showalter, Sean M. Tobyne, Álvaro Pascual‐Leone · 2026 · Frontiers in Neurology
  4. Pilot feasibility, acceptability, and tolerability of researcher-delivered apolipoprotein E ( APOE ) disclosure via videoconferencing in Australian adults at-risk of dementia
    Emily Rosenich, Simran Chauhan, Ruby Haeusler, Mirette Keriakes, Hannah Cummins, Hannah Olver, Lisa Bransby, Paul T. Maruff, Yen Ying Lim · 2026 · Journal of Alzheimer s Disease
  5. Peptide vaccination for Alzheimer's disease: Immunological foundations, therapeutic potential, and translational barriers
    Haoteng Chen, Y Y Lin, DeZhi Kang, Tong Zhao · 2026 · Journal of Alzheimer s Disease Reports
  6. Glycopolymers as emerging modulators of Amyloid-β aggregation: structure-activity relationships and therapeutic potential
    Emanuel Cardoso, Arménio Coimbra Serra, Jorge F. J. Coelho, Patrícia Pereira · 2026 · Carbohydrate Polymers
  7. MCH‐Guard: Multimodal machine learning framework for risk stratification of cerebral microhemorrhage risk in the Alzheimer's Disease Neuroimaging Initiative
    Alper Gel, Eliana Phillips, Isabella Hausle, Pamela Thropp, Duygu Tosun, Alzheimer’s Disease Neuroimaging Initiative · 2026 · Alzheimer s & Dementia
  8. Travel barriers to amyloid‐targeting infusion access among older adults
    Jeremy Burke, Albert Weerman, Mark Hanson, Quanwu Zhang, Amir Abbas Tahami Monfared, Soeren Mattke · 2026 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  9. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology
    Xiaoxuan Xing, Ke Wang, Yingnan Feng, Chao Wu, Lihua Jia, Huiying Li, Zhiyong Wen, Yinan Tang, Zi Wang, Xiaotong Zhang et al. · 2026 · Frontiers in Psychiatry
  10. Multiomics and proteomic insights into Alzheimer’s disease biology in Down syndrome
    Mitchell Martá-Ariza, T R Wisniewski · 2026 · Expert Review of Neurotherapeutics
  11. The contribution of Laboratory Medicine to Precision Neurology
    Lorenzo Gaetani, Giovanni Bellomo · 2026 · Clinical Chemistry and Laboratory Medicine (CCLM)
  12. Potential and biases of large language model simulation for public surveys on Alzheimer's disease therapies
    Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Kazushi Suzuki, Atsushi Iwata, Takeshi Iwatsubo · 2026 · Journal of Alzheimer s Disease
  13. Variable Aβ tracer uptake in hyperostosis frontalis interna: implications for brain Aβ PET/CT interpretation
    Joseph M. Ryan, Hina J. Shah, Michael P. McCormick, Alberto Serrano‐Pozo · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  14. Development of a picture‐based tool for subjective deficits in cognition and ADLs
    Isabell Ballasch, Ronja V. Fassbender, Oezguer A. Onur, Sophia Felicitas Schuh, Nils Richter, Esra Kara, Anna Sauerbier, Ulrike Lambotte, Haidar Salimi Dafsari, Jutta Stähl et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  15. Mitochondrial genome as a therapeutic target — from evolutionary biology of the honeybee to personalized human medicine: A scoping review
    Serik D. Nurbaev · 2026 · Кубанский научный медицинский вестник
  16. Distinct spatial patterns of perivascular spaces enlargement for multiple and Co-existing pathologies of cognitive impairment
    Woosik Kim, Yejin Hwang, Yelim Yang, Min Gyeong Kim, Hyemin Jang, Seung Hong Choi, Joon‐Kyung Seong, Roh‐Eul Yoo, Wha Jin Lee · 2026 · The Journal of Prevention of Alzheimer s Disease
  17. Morbidity and medication use preceding a diagnosis of late-onset Alzheimer’s disease: a Danish nationwide study
    Cecilia El-Sayed Petersen, Line Damsgaard, Janet Janbek, Thomas Munk Laursen, Karsten Vestergaard, Hanne Gottrup, Gunhild Waldemar · 2026 · Journal of Neurology
  18. Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab
    Nicholas U. Schwartz, Connor D. Dietz, Zoe Lin, Gautam Tammewar, Nhat Bui, Renaud La Joie, Yingbing Wang, Anirudh Sreekrishnan, Dror Suhami, Lawren A. VandeVrede et al. · 2026 · Neurocase
  19. Advances in the Diagnosis and Management of Alzheimer’s Disease
    Pallavi Joshi, Po‐Heng Tsai, Andrew Alix, Ganesh Gopalakrishna · 2026 · Advances in Psychiatry and Behavioral Health
  20. Accelerated Deep-Learning-Based Image Reconstruction for 3D T2 Dark-Fluid in Imaging of Multiple Sclerosis
    Sebastian Altmann, Mario Alberto Abello Mercado, Arwed Elias Michael, Mariya Kondova, Roman H. Paul, Dominik Marcel Nickel, Vanessa Ines Schöffling, Vinzenz Fleischer, Marc A. Brockmann, Ahmed E. Othman · 2026 · Investigative Radiology
  21. Dynamic light scattering spectroscopy and the Centiloid scale
    Jeffrey N. Weiss, Daryl Eber, Rebel Cole · 2026 · Journal of Alzheimer s Disease
  22. Eligibility for lecanemab therapy in a biomarker defined memory clinic cohort: A five-year analysis
    Pablo Agüero, J. Roa Escobar, Raquel Téllez, Verónica Mañanes Barral, Estrella Gómez‐Tortosa · 2026 · Journal of Alzheimer s Disease
  23. APOE ε4 and Alzheimer's disease biomarkers in an American Indian community
    Matti J. Matheson, René Labounek, Adam D. Block, Corey Strong, Ann J. Robertson, Adam Hansen, Meghan Kremer, Ashley J. Petersen, Annamarie Hill, Breton Michael Asken et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  24. Real-world safety and implementation challenges of lecanemab therapy for Alzheimer’s disease in South Korea: a single-center experience
    Hyemin Jang, Jae Seung Kim, Jung Won Hwang, Da Woon Jeong, Jeongeun Ka, Da Min Kang, Chong Hyun Suh, Yangsean Choi, Minyoung Oh, Jae Seung Kim et al. · 2026 · Alzheimer s Research & Therapy
  25. APOE genotype is associated with Ex vivo inflammatory responses in healthy individuals: Potential implications for Alzheimer's disease
    Joan Y. Song, Liane E. Hunter, Yun Freudenberg‐Hua, Naomi Lubin, Shanshan Hu, Kenny Ye, Richard B. Lipton, Christopher G. Engeland, Michael L. Lipton · 2026 · Brain Behavior & Immunity - Health
  26. The Role of Primary Care Physicians in Early Diagnosis and Management of Dementia: A Narrative Review for Clinical Practice
    Kaitlyn Alessi, Charles Sarria, Nehabahen Chauhan, Naushira Pandya, Mayur S. Parmar · 2026 · SN Comprehensive Clinical Medicine
  27. Hospital Budget Impact and Provider-Side Economic Evaluation of Lecanemab and Donanemab Under Japan’s National Fee Schedule: A Head-to-Head Linear Model
    Kotaro Makita, Takuto Nishihara, Yuta Arakaki, Tomoya Ohida, Kosei Goto, Nobuo Kutsuna · 2026 · Value in Health Regional Issues
  28. Patient and representative experience after amyloid PET/CT in a real-world memory clinic: a mixed-methods observational study
    Giulia Richina, Nathalie Testart Dardel, Paolo Salvioni Chiabotti, Gilles Allali, John Olivier Prior, Mario Jreige · 2026 · EJNMMI Reports
  29. From biomarker expansion to equitable implementation in mild cognitive impairment
    Mashal Khan, Talha Khan, Ayesha Tariq · 2026 · Neurological Sciences
  30. Projected lecanemab wastage from vial discard: Simulation based on Japanese interim post-marketing surveillance summary statistics
    Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Takeshi Iwatsubo · 2026 · Journal of Alzheimer s Disease
  31. The Clearance-Centered Bottleneck in Alzheimer’s Disease: From Coupled Glymphatic–Lymphatic Circuits to Therapeutic Opportunities
    Peijuan Wu, Yuhui Liao, Changyan Liu, Xiaoying Liu, Qin Feng, Xunshu Cheng · 2026 · Molecular Neurobiology
  32. Landscape of Apolipoprotein (APOE) in the Emirati Population and Recommendations for a Genotyping Approach for Amyloid-Beta Monoclonal Antibodies (Aβ-mAbs) in Alzheimer’s Disease Patients
    Wadha Mohammed, Mohamed Al Ameri, Sahar Al Marzooqi, Habiba S. AlSafar, Roland Olbrich, Mira Mousa, Dalia Barayan, Tiago R. Magalhães, Javier Quilez, Judith Reche et al. · 2026 · Cureus
  33. Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease
    Alyanna Ferrer, Justin Moon · 2026 · Journal of Alzheimer s Disease Reports
  34. The impact of supplements on cognitive function for Alzheimer's disease or mild cognitive impairment: a systematic review and network meta-analysis
    Yafang Li, Qi Leng, Yunyun Wang · 2026 · Nutritional Neuroscience
  35. Identifying facility-level and infrastructure-level bottlenecks in Japan's lecanemab rollout through an online survey of dementia specialists
    Saki Nakashima, Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kiyotaka Nemoto, Tetsuaki Arai, Shinji Higashi, Ataru Igarashi, Kensaku Kasuga et al. · 2026 · Journal of Alzheimer s Disease Reports
  36. Worry and Anxiety in the Era of Early Diagnosis and Disease Modifying Treatment for Alzheimer’s Disease
    Shana D. Stites, Katherine Lee, Carolyn Kuz, David S. Mandell, Hillary R. Bogner, Rebecca T. Brown · 2026 · Current Psychiatry Reports
  37. Crosstalk of Gastrointestinal Pathogen Infection, Food Allergy, and Neuroinflammation in Alzheimer’s Disease
    Bin (Brenda) Su, Chun Xu · 2026 · Archives of Depression and Anxiety
  38. Automated quantification of white matter hyperintensity confluence: A measure of spatial organisation beyond volume and visual rating scales
    Tatjana Schmidt, Robert Salzmann, Marcella Montagnese, Dennis Chan, Jose Bernal, Malte Pfister, Philipp Arndt, Oliver Peters, Julian Hellmann‐Regen, Lukas Preis et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  39. Advances in modified anti-Aβ antibodies for the treatment of Alzheimer’s disease
    Shuang Li, Jiwei Gu, Zucai Xu, Chunyang He, Changyin Yu · 2026 · BMC Medicine
  40. [18F]Florapronol (Alzavue®) Amyloid Burden and 4-Year [18F]FDG Metabolic Neurodegeneration in Amnestic Mild Cognitive Impairment
    Su Yeon Park, Inki Lee, I. Lim, Byung Il Kim, D. Chi, Byeong Hyeon Byeon, J. Ha · 2026 · Nuclear medicine and molecular imaging
  41. Spectrum of amyloid-related imaging abnormalities associated with aducanumab treatment: a case series report
    Alireza Atri, Gioacchino G. Curiale, Paul S. S Aisen, Jerome A. Barakos, Derk D. Purcell, Luc Bracoud, Samantha Budd Haeberlein, Christina Grassi, Richard Hughes, Karen Vossen Smirnakis · 2026 · BMC Neurology
  42. Developing Deep Learning Methods for Cognitive Impairment Detection Based on Non-invasive Data
    Muath Alsuhaibani · 2025
  43. Druggable Pathophysiologic Targets in Alzheimer Disease: From Amyloid and Tau to Biomarker-Guided Multimodal Therapy
    Jiwon Park · 2026 · Dementia and Neurocognitive Disorders
  44. Therapeutic Time Window of Disease‐Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J‐ ADNI Study
    Saki Nakashima, Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Kazushi Suzuki, Atsushi Iwata, Wataru Satake, Takeshi Iwatsubo, Japanese Alzheimer's Disease Neuroimaging Initiative · 2026 · Geriatrics and gerontology international/Geriatrics & gerontology international
  45. Heterogeneity in plasma p‐tau217 response and its association with cognitive trajectories under lecanemab treatment
    Sung Hoon Kang, Yu Jeong Park, Seungyun Lee, Jimin Kang, 이성인, Eun Seong Lee, Hye Na Jung, Inseon Ryoo, Hyundoo Hwang, Kwangho Choi et al. · 2026 · Alzheimer s & Dementia
  46. Low-dose CT for MRI-free quantification of tau PET in Alzheimer’s disease: a multicentre, cross-sectional, comparison study
    Guilherme Povala, Lívia Amaral, Bruna Bellaver, Firoza Zubeida Lussier, Pâmela C.L. Ferreira, Douglas Teixeira Leffa, Guilherme Bauer‐Negrini, Raphael de Luca e Tuma, Álvaro de Oliveira Franco, Cécile Tissot et al. · 2026 · The Lancet Medical Imaging & Theranostics
  47. An Integrative Multimodal Model for Early Diagnosis of Dementia and Differential Diagnosis of Alzheimer’s Disease Using Neuroimaging, Polygenic Risk, and Cognitive Assessments
    Tahir Tekin Filiz, Vera Fominykh, Karin Persson, Mona Michelet, Iris Broce, Ingrid Tøndel Medbøen, Stina Aam, Alexey Shadrin, Dag Alnæs, Lavinia Athanasiu et al. · 2026 · medRxiv
  48. Artificial intelligence and machine learning for precision prevention of cognitive decline: integrating multimodal biomarkers, lifestyle interventions, and natural medicines from prediction to clinical practice
    Erika Smeriglio, Martina Imbesi, Jianbo Xiao, Antonella Smeriglio, Domenico Trombetta · 2026 · Frontiers in Aging Neuroscience
  49. Performance of the participant self-rating version of the Quick Dementia Rating System in a racially diverse cohort of non-demented older adults
    Felicia C. Goldstein, Chadwick M. Hales, Monica W. Parker, Antoine R Trammell, Cecelia M. Manzanares, Samantha C. Heldenberg, John Hanfelt, Allan I. Levey, James J. Lah · 2026 · Journal of Alzheimer s Disease
  50. Why dementia is often not diagnosed by subtype: care pathways and imaging access in the United Arab Emirates
    Syed Fahad Javaid, Fadwa Al Mugaddam, Zubaida Shebani, Syed Ali Bokhari · 2026 · Frontiers in Psychiatry
  51. The Challenge of Atypical Alzheimer Disease Phenotypes
    Călin I. Prodan, Andriy Yabluchanskiy · 2026 · Neurology
  52. Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort
    Aida Fernández‐Lebrero, Joan Jiménez-Baladó, Greta García‐Escobar, José Contador, Isabel Estragués-Gázquez, Laia Peraferrer-Montesinos, Rosa María Manero-Borràs, Laura Ludovica Gramegna, Marc Viles-García, Ana Rodríguez-Campello et al. · 2026 · Alzheimer s & Dementia
  53. THERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB
    Mikołaj Jońca, Gabriela Majchrowicz, Natasza Kurys, Weronika Piekarska, Szymon Litke, Katarzyna Gołacka · 2026 · International Journal of Innovative Technologies in Social Science
  54. Thriving in Complexity Through Interdisciplinary Collaboration
    Demetra E. Antimisiaris, Patricia W. Slattum · 2026 · The Senior Care Pharmacist
  55. Letter to the Editor “Therapeutic Time Window of Disease‐Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J‐ ADNI Study”
    Suman Pradhan · 2026 · Geriatrics and gerontology international/Geriatrics & gerontology international
  56. Rational drug design for Alzheimer’s disease: from approved therapies to next-generation clinical candidates and AI-guided innovation
    Sana Saffour, Turgut Seçkin Gül, Halise Inci Gul · 2026 · Future Medicinal Chemistry
  57. Real‐world implementation of lecanemab in Korean patients at a tertiary memory clinic: Safety, ARIA risk, and early treatment patterns
    Jaemin Shin, S J Suh, Yu Jeong Park, Seungyun Lee, Jimin Kang, Eun Seong Lee, Hye Na Jung, Inseon Ryoo, Seongin Lee, Jae Seon Eo et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  58. Considerations for using amyloid-targeting therapies for the treatment of early symptomatic Alzheimer’s disease
    Andrew E. Budson, Peter Alexander Ljubenkov, Aaron Ritter, Cara Leahy, Vijay K. Ramanan, Jared R. Brosch, Anna Burke, Brandy R. Matthews · 2026 · Frontiers in Neurology
  59. Entwicklung der Pharmakotherapie von Menschen mit Demenz in Deutschland 2016-2025: Langfristige Trends in der hausärztlichen und neurologisch-psychiatrischen Versorgung
    Jens Bohlken, Karel Kostev · 2026 · Psychiatrische Praxis
  60. The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy
    Eric Dinnerstein · 2026 · The Journal of Prevention of Alzheimer s Disease
  61. Alzheimer’s Disease as a Multi-Layer Network Disorder: A Systems Biology Framework Integrating Multi-Omics Mechanisms
    Muhammed H. Alzweiri, Ahmed S.A. Ali Agha, Nidal Adel Qinna, Ghayda’ AlDabet, Thaqif El Khassawna, Talal A. Aburjai · 2026 · Biomedicines
  62. Medical comorbidities of patients receiving amyloid‐targeting treatments in a memory clinic
    William J. B. Powell, Suzanne E. Schindler, Martí Jiménez‐Mausbach, Inez Y. Oh, Anna Hofmann, Barbara Joy Snider, Madeline Paczynski, Nupur Ghoshal, Philip R.O. Payne, Albert M. Lai et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  63. Long‐term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study
    María Pascual‐Lucas, Ana Ma Lacosta, María Montañés, Jesús Canudas, Jorge Loscos, Inmaculada Monleón, José Antonio Allué, Leticia Sarasa, Noelia Fandos, Judith Romero et al. · 2026 · Alzheimer s & Dementia
  64. Dementias
    Julia Czech, Charlotte S. Weyland, Manuela Neumann, Alexander E. Drzezga, Jörg Bernhard Schulz · 2026 · Springer eBooks
  65. Clinical Alzheimer's biomarker disclosure experiences among patients and family members
    Melany Medina, Eunji Russ, Megan Gage Witbracht, Dianxu Ren, Melissa L. Knox, Gil Dan Rabinovici, Jennifer Hagerty Lingler, Joshua D. Grill · 2026 · Alzheimer s & Dementia Behavior & Socioeconomics of Aging
  66. Alzheimer’s disease blood biomarkers reveal proteomic modules of disease progression
    Robert R. Butler, Michael P. Brown, Audrey Weber, Gregory A. Cary, Yann Le Guen, Patricia Morán Losada, Justin H. Mendiola, Victor W. Henderson, Sharon J. Sha, Kathleen L. Poston et al. · 2026 · medRxiv
  67. Fluid and Imaging Biomarkers in Lecanemab Therapy for Early Alzheimer’s Disease: Current Evidence, ARIA Risk Prediction, and Treatment Monitoring
    Pan‐Woo Ko · 2026 · Journal of dementia and Alzheimer's disease
  68. Current Practice and Long-Term Developments in Multidisciplinary Dutch Memory Clinics
    Stephan Duijkers, Daphne ter Huurne, Marco Blom, Hanna E. Bodde, Jolanda H. M. Dobbe, Wiesje M. van der Flier, Willemijn J. Jansen, Marcel Olde Rikkert, Janne M. Papma, Frans R.J. Verhey et al. · 2026 · Journal of Geriatric Psychiatry and Neurology
  69. AI-aided neuroimaging for the diagnosis of Alzheimer's disease: A concise review of recent studies
    Yeonwoo Lee, Priscilla Nadalin, Emre Onemli, Rafi Hadad, Fengyi Yu, Lior Greenbaum, Alon Greenbaum, Jinhyun Ahn · 2026 · Heliyon
  70. Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions
    Matija Zupan, Polona Rus Prelog, Milica Gregorič Kramberger, Senta Frol · 2026 · Frontiers in Neurology
  71. Adaptation and feasibility of the International Registry for Alzheimer's Disease and Other Dementias real-world datasets in old-age mental healthcare practice in China
    Haifeng Zhang, Jinghan Lai, Tao Wang, Tao Li, Sha Liu, Daliang Sun, Wei Chen, Weihong Kuang, Xia Li, Ming Zhang et al. · 2026 · Journal of Alzheimer s Disease
  72. Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease
    Steven Mark Greenberg, Costantino Iadecola, Sherry Chou, Petrice M. Cogswell, Mitchell S.V. Elkind, William J. Hicks, Caitlin Le, Deborah A. Levine, Richard B. Lipton, Lauren M. Massimo et al. · 2026 · Journal of the American Heart Association
  73. Neurokognitive Störungen
    Lutz Frölich, Lucrezia Hausner, Frank Schneider · 2026 · Springer eBooks
  74. Anti‐amyloid immunotherapy and brain volume trajectories in early‐onset versus late‐onset Alzheimer's disease
    Rashi I. Mehta, Methasit Jaisa-aad, Camila Vieira Ligo Teixeira, Patrick D. Worhunsky, Joseph E. Malone, Melanie Ward, Cierra M. Keith, Holly E. Phelps, Khalid Sharif, Stephanie Pockl et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  75. Beyond Targeted Gene Panels: Whole-Exome Sequencing as a Strategic Platform for Precision Therapeutics in Alzheimer’s Disease
    Carlos Perezcano, Mariana Pérez-Coria, Ángel Ricardi-Mendoza · 2026 · Life
  76. APOE ‐guided lecanemab dosing dissociates ARIA‐E from ARIA‐H: The K‐ROAD study
    Heekyoung Kang, Hyemin Jang, Jehyun Ahn, Duk L. Na, Jae–Hong Lee, Eun‐Joo Kim, Min Young Chun, Soo Hyun Cho, Byeong Chae Kim, Si Eun Kim et al. · 2026 · Alzheimer s & Dementia
  77. Two serial MoCA assessments may support biomarker-sparing triage between Parkinson’s disease/Lewy body dementia and frontotemporal dementia: a progressive inclusion analysis of 1,129 participants
    Wei Lin, Sanjeet Singh Grewal, Richard W. Byrne · 2026 · Frontiers in Aging Neuroscience
  78. NEW THERAPEUTIC OPPORTUNITIES IN ALZHEIMER'S DISEASE: THE ROLE OF ANTI-AMYLOID ANTIBODIES: A COMPREHENSIVE REVIEW
    Kacper Jaskulski, Katarzyna Kowalenko, Jan Szadkowski, Krzysztof Wichman, Hanna Kasprzak, Yana Lavrenchuk, Natalia Drobinska, Natalia Maria Leśniak, Julia Aleksandra Leśniak, Zuzanna Olszowiec · 2026 · International Journal of Innovative Technologies in Social Science
  79. Cerebrospinal Fluid Amyloid‐β Risk Stratification in Cerebral Amyloid Angiopathy: A Missing Link for Anti‐Amyloid Therapy Safety
    Hajime Takase · 2026 · Annals of Neurology
  80. Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series
    Jayoung Han, Yuan Fang, Darlingtina Kenechi Esiaka, Olufunmilola Abraham · 2026 · Frontiers in Psychiatry
  81. SWI versus T2*GRE for ARIA-H monitoring: a pragmatic perspective on adoption in clinical practice
    Meike Willemijn Vernooij, Tiago Gil Oliveira, Roland Wiest, Nick C. Fox, Giovanni Battista Frisoni, Frederik Barkhof · 2026 · Neuroradiology
  82. Amyloid-Targeting Treatments in Patients With Non–Alzheimer Disease Copathologies
    Andy J. Liu, Suzanne E. Schindler, Heather Elizabeth Whitson · 2026 · JAMA Neurology
  83. Anti-Amyloid Antibodies in the Treatment of Alzheimer’s Disease: An Umbrella Review
    Stefania Kalampokini, Iraklis Keramidiotis, Antonis Frontistis, Francesca Zuchi, Dimitrios Michmizos, Vasileios T. Papaliagkas, Effrosyni Koutsouraki · 2026 · Journal of Clinical Medicine
  84. Stellenwert der Alzheimertherapie mit Anti-Amyloid-Antikörpern
    Jörg Bernhard Schulz · 2026 · DNP – Die Neurologie & Psychiatrie
  85. FDG-PET in Cognitive Impairment and Dementia
    Julie Hong, Daniel H.S. Silverman · 2026 · PET Clinics
  86. Anti-Amyloid-Therapien: Evidenz, Verantwortung und klinische Umsetzung
    J. Goedecke, Gereon R. Fink, Oezguer A. Onur · 2026 · DGNeurologie
  87. Sex-Specific Machine Learning–Enabled Risk Prediction for Dementia Using Cardiovascular Risk Factors
    Jingzhi Yu, John J. Stephen, Lucia C. Petito, Abigail Gauen, Lihui Zhao, Maxwell Armand Mansolf, Elizabeth Peterson, Rachel Zmora, Denise M. Scholtens, Katherine Giorgio et al. · 2026 · Neurology Open Access
  88. Novel therapies in Alzheimer’s disease
    Denis Pavăl, Octavia Căpățînă, Mihaela Fadgyas Stănculete · 2026 · International review of neurobiology
  89. Baseline plasma C1q and C3 as potential biomarkers for lecanemab efficacy and ARIA risk in early Alzheimer's disease
    Gihwan Byeon, Jung-Won Lee, Suhyung Kim, Yoo Hyun Um, Sheng‐Min Wang, Seunggyun Ha, Sonya Youngju Park, Ilah Shin, Jinhee Jang, Chang Uk Lee et al. · 2026 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  90. Symptomatic lobar intracerebral hemorrhage during extended lecanemab treatment: A case report
    Yugo Takahashi, Naoyuki Shiraishi, Akihiro Tsukahara, Yukari Matsuda, Takuya Nishina, Hiroo Yoshikawa, Takashi Uzu, Etsuro Mori · 2026 · Journal of Alzheimer s Disease Reports
  91. Elecsys pT181p immunoassay: Clinical performance for ruling out amyloid pathology
    Craig William Ritchie, Sayuri Hortsch, Clara Quijano‐Rubio, Patrick Menzel, Imke Kirste, David Caley, Anna D. Burke, Christopher C. Rowe, Marc Suárez‐Calvet, Dag Aarsland et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  92. Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab
    Ülkü Figen Demır, Fatmanur Karakuş Dilbaz · 2026 · Neurology International
  93. A Cross‐Sectional Survey of Knowledge, Confidence, and Decision‐Making in Acute Stroke in the Era of Anti‐Amyloid Therapies
    Preeyaporn Sarangarm, Nicole M. Acquisto, David E. Zimmerman, Adis Keric, Christian Kroll, Brett A. Faine, Megan A. Rech, EMPHARM‐NET · 2026 · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
  94. The path to treating multiple-etiology dementia: Combining vascular risk control and disease-modifying neurodegenerative therapies
    Adam de Havenon, Kevin N. Sheth, Carolyn A. Fredericks, Adam M. Brickman · 2026 · Neurotherapeutics
  95. Drug–Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis
    Tsuyoshi Nakai, Takenao Koseki, Hirohisa Watanabe, Shigeki Yamada · 2026 · medRxiv
  96. Imaging for anti‐amyloid therapy eligibility: Comparing GRE and SWI in detecting microhemorrhages and superficial siderosis
    Jeremy N. Ford, Suely Fazio Ferraciolli, Odette Ganem Chagui, Marvin Relerford, Esteban Calle, John Dickson, Maryam Vejdani‐Jahromi, Matthew Nicholas Desalvo, Liliana A Ramirez Gomez, Seonghwan Yee et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  97. Structural Brain Imaging for Newly Diagnosed Cognitive Impairment by Medicare Coverage Type
    Soeren Mattke, Ying Liu, Wei Ye, Kimberly Altunkaynak · 2026 · Journal of the American College of Radiology
  98. From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer’s Disease
    Robert Perneczky, Frank Jessen, Timo Grimmer, Johannes Levin, Anna Hufnagel, Agnes Flöel, Oliver Peters, Lutz Froelich, Anna Hofmann · 2026 · CNS Drugs
  99. Cognitive Well-Being: A Clinical Review of Brain Health, Dementia Risk Reduction, and Emerging Biomarkers for the Osteopathic Family Physician
    Joey R. Gee · 2026 · Journal of the Osteopathic Family Physicians of California
  100. Amyloid-beta-targeting monoclonal antibodies in early Alzheimer’s disease: a cochrane review summary and appraisal for the neurological community
    Diogo Haddad Santos, Anderson Matheus Pereira da Silva · 2026 · Neurological Sciences